Thermo Fisher Scientific Baltics, UAB - financials and debts
Company age: 32 y. 7 mo.
Thermo Fisher Scientific Baltics - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 294,891,330 | 440,108,453 | 1,263,539,526 | 1,941,513,774 | 1,476,888,454 | 820,979,642 | 790,272,619 | 491,173,060 |
| Profit before tax | 183,713,819 | 282,235,191 | 472,752,746 | 715,075,461 | 626,492,901 | 392,892,350 | 508,582,964 | 236,989,713 |
| Net profit | 150,993,440 | 246,597,137 | 405,474,058 | 618,076,247 | 554,487,842 | 348,627,163 | 450,984,395 | 206,362,715 |
| Equity | 588,766,351 | 835,363,488 | 1,240,837,546 | 1,858,913,793 | 803,401,635 | 1,185,632,535 | 1,636,616,930 | 1,842,979,645 |
| Liabilities | 28,310,408 | 40,745,829 | 577,056,709 | 395,464,413 | 109,024,044 | 56,509,240 | 70,244,356 | 188,979,273 |
| Non-current assets | 109,210,049 | 102,710,566 | 152,671,062 | 191,037,408 | 185,763,567 | 177,763,702 | 167,757,489 | 1,655,505,409 |
| Current assets | 510,582,147 | 775,439,119 | 1,667,526,913 | 2,071,724,599 | 736,264,315 | 1,073,371,688 | 1,546,185,289 | 380,209,995 |
| Total assets | 619,792,196 | 878,149,685 | 1,820,197,975 | 2,262,762,007 | 922,027,882 | 1,251,135,390 | 1,713,942,778 | 2,035,715,404 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 58,348,149 | 38,912,474 | 62,422,907 |
| Social insurance contributions | - | - | - | - | - | 12,462,307 | 12,318,104 | 13,554,057 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +39.6% | +49.2% | +187.1% | +53.7% | -23.9% | -44.4% | -3.7% | -37.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 24.4% | 28.1% | 22.3% | 27.3% | 60.1% | 27.9% | 26.3% | 10.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 25.6% | 29.5% | 32.7% | 33.2% | 69.0% | 29.4% | 27.6% | 11.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 51.2% | 56.0% | 32.1% | 31.8% | 37.5% | 42.5% | 57.1% | 42.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 62.3% | 64.1% | 37.4% | 36.8% | 42.4% | 47.9% | 64.4% | 48.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.0 | 0.5 | 0.2 | 0.1 | 0.0 | 0.0 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 357,011 | 470,746 | 1,135,596 | 1,199,329 | 793,670 | 503,617 | 511,421 | 330,330 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Thermo Fisher Scientific Baltics - Social security debts
The company had no debts to Sodra
Thermo Fisher Scientific Baltics - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Thermo Fisher Scientific Baltics, UAB (code 122351387) is a Private Limited Liability Company engaged in the manufacture of other chemical products n.e.c. In 2025, the company generated EUR 491.17 million in revenue and EUR 206.36 million in net profit, with a profit margin of 42.0%. Revenue declined by 37.9% year on year and was 40.2% lower than two years earlier, indicating a weaker top-line performance in the latest year. Even so, profitability remained strong, supported by a substantial net profit base. Over the three-year period, revenue moved from EUR 820.98 million in 2023 to EUR 790.27 million in 2024 and then to EUR 491.17 million in 2025, while net profit was EUR 348.63 million, EUR 450.98 million and EUR 206.36 million respectively. The balance sheet strengthened further in 2025, with total assets of EUR 2.04 billion, equity of EUR 1.84 billion and liabilities of EUR 188.98 million. Key ratios included ROE of 11.2%, ROA of 10.1%, debt-to-equity of 0.10 and asset turnover of 0.24x. Revenue per employee was EUR 330.5K.